Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8808 |
High Similarity |
NPD4965 |
Approved |
0.8808 |
High Similarity |
NPD4967 |
Phase 2 |
0.8808 |
High Similarity |
NPD4966 |
Approved |
0.8693 |
High Similarity |
NPD6234 |
Discontinued |
0.8609 |
High Similarity |
NPD37 |
Approved |
0.8523 |
High Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.8462 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8354 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.8322 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.8313 |
Intermediate Similarity |
NPD7228 |
Approved |
0.811 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7986 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7964 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.774 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7721 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7716 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7671 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7651 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7647 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7589 |
Intermediate Similarity |
NPD17 |
Approved |
0.7578 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7576 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7556 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7552 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7531 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.75 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.75 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7467 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7439 |
Intermediate Similarity |
NPD919 |
Approved |
0.7438 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7431 |
Intermediate Similarity |
NPD1608 |
Approved |
0.743 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7423 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7415 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.741 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.74 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7381 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7376 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7362 |
Intermediate Similarity |
NPD5353 |
Approved |
0.7361 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7353 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7351 |
Intermediate Similarity |
NPD1933 |
Approved |
0.7346 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7326 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.732 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7308 |
Intermediate Similarity |
NPD5006 |
Approved |
0.7308 |
Intermediate Similarity |
NPD5005 |
Approved |
0.7305 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7301 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7294 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7294 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7284 |
Intermediate Similarity |
NPD6386 |
Approved |
0.7284 |
Intermediate Similarity |
NPD6385 |
Approved |
0.7278 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5585 |
Approved |
0.7267 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7261 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7251 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7237 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7222 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7211 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7205 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7197 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7195 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7195 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7195 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7188 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7182 |
Intermediate Similarity |
NPD4420 |
Approved |
0.7179 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD1613 |
Approved |
0.717 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7168 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7161 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7161 |
Intermediate Similarity |
NPD2531 |
Phase 2 |
0.7153 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7153 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7152 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7143 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7133 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7126 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7125 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7125 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7125 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7125 |
Intermediate Similarity |
NPD3688 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD3146 |
Approved |
0.7125 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7115 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.711 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7107 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7105 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7105 |
Intermediate Similarity |
NPD8032 |
Phase 2 |
0.7095 |
Intermediate Similarity |
NPD7296 |
Approved |
0.7091 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7091 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7091 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7089 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7089 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7089 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7086 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7073 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7069 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7067 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7066 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7047 |
Intermediate Similarity |
NPD3266 |
Approved |
0.7047 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7047 |
Intermediate Similarity |
NPD3267 |
Approved |
0.7044 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7041 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7039 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7039 |
Intermediate Similarity |
NPD1296 |
Phase 2 |
0.7037 |
Intermediate Similarity |
NPD920 |
Approved |
0.7027 |
Intermediate Similarity |
NPD4359 |
Approved |
0.7027 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7021 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7018 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7018 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7018 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7006 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7006 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.6993 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6989 |
Remote Similarity |
NPD7280 |
Phase 3 |
0.6989 |
Remote Similarity |
NPD7281 |
Phase 3 |
0.697 |
Remote Similarity |
NPD6873 |
Phase 2 |
0.6966 |
Remote Similarity |
NPD1894 |
Discontinued |
0.6964 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6963 |
Remote Similarity |
NPD7827 |
Phase 1 |
0.6962 |
Remote Similarity |
NPD5958 |
Discontinued |
0.6957 |
Remote Similarity |
NPD1511 |
Approved |
0.6951 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6951 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6946 |
Remote Similarity |
NPD5402 |
Approved |
0.6943 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6943 |
Remote Similarity |
NPD6099 |
Approved |
0.6943 |
Remote Similarity |
NPD6100 |
Approved |
0.6943 |
Remote Similarity |
NPD3539 |
Phase 1 |
0.6939 |
Remote Similarity |
NPD3847 |
Discontinued |
0.6928 |
Remote Similarity |
NPD3764 |
Approved |
0.6928 |
Remote Similarity |
NPD3384 |
Approved |
0.6928 |
Remote Similarity |
NPD3382 |
Approved |
0.6928 |
Remote Similarity |
NPD3268 |
Approved |
0.6928 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6928 |
Remote Similarity |
NPD3383 |
Approved |
0.6923 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6923 |
Remote Similarity |
NPD6111 |
Discontinued |
0.6918 |
Remote Similarity |
NPD5691 |
Approved |
0.6918 |
Remote Similarity |
NPD6674 |
Discontinued |
0.6918 |
Remote Similarity |
NPD1243 |
Approved |
0.6914 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6914 |
Remote Similarity |
NPD642 |
Clinical (unspecified phase) |
0.6908 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6906 |
Remote Similarity |
NPD1358 |
Approved |
0.6905 |
Remote Similarity |
NPD5019 |
Clinical (unspecified phase) |
0.6905 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6903 |
Remote Similarity |
NPD447 |
Suspended |
0.6899 |
Remote Similarity |
NPD1375 |
Discontinued |
0.6899 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6894 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.689 |
Remote Similarity |
NPD4210 |
Discontinued |
0.6889 |
Remote Similarity |
NPD7235 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6879 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6879 |
Remote Similarity |
NPD2799 |
Discontinued |
0.6871 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD1512 |
Approved |
0.6867 |
Remote Similarity |
NPD1876 |
Approved |
0.6867 |
Remote Similarity |
NPD7411 |
Suspended |
0.6864 |
Remote Similarity |
NPD6971 |
Discontinued |
0.6864 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6859 |
Remote Similarity |
NPD6653 |
Approved |
0.6855 |
Remote Similarity |
NPD4534 |
Discontinued |
0.6839 |
Remote Similarity |
NPD1240 |
Approved |
0.6835 |
Remote Similarity |
NPD3134 |
Approved |
0.6835 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6829 |
Remote Similarity |
NPD5403 |
Approved |
0.6818 |
Remote Similarity |
NPD5110 |
Phase 2 |
0.6818 |
Remote Similarity |
NPD5109 |
Approved |
0.6818 |
Remote Similarity |
NPD5111 |
Phase 2 |
0.6813 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.681 |
Remote Similarity |
NPD5401 |
Approved |
0.681 |
Remote Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.6807 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6802 |
Remote Similarity |
NPD7315 |
Approved |
0.68 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6796 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.6795 |
Remote Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.6795 |
Remote Similarity |
NPD4618 |
Approved |
0.6795
|
Remote Similarity |
NPD4622 |
Approved |